Bare Metal Stents and Drug Eluting Stents in Patients Who Underwent Blood Transfusion

Bare-metal Stents(BMS) Versus Drug-eluting Stents(DES) in Patients Who Underwent Periprocedural Blood Transfusion : A Nationwide Longitudinal Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03788148

Acronym

TFPCI2

Enrollment

28322

Registered

2018-12-27

Start date

2018-01-03

Completion date

2018-11-30

Last updated

2018-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erythrocyte Transfusion, Percutaneous Coronary Intervention, Revascularization

Keywords

transfusion, PCI, DES, BMS

Brief summary

Retrospective cohort study of Korean National Healthcare Insurance Database. To investigate clinical outcomes of bare metal stents versus drug eluting stents in patients who underwent periprocedural red blood cell transfusion.

Detailed description

A Korean nationwide, multi-center, retrospective observational cohort study. The receipt of red blood cell transfusion is at high risk of cardiac events or death. But little is know regarding the comparative outcomes of BMS and DES implantation in patients who underwent periprocedural red blood cell transfusion. Longitudinal data is collected from administrative claims in the national health insurance services of Korea. All Korean data(N=500,591) undergoing PCI from 2006 to 2015 is extracted. BMS or DES Patients(N=28,322) who received periprocedural red blood cell transfusion is investigate. Clinical outcomes until December 31, 2017 is investigate. Primary endpoint is a time to the first major adverse clinical event(MACE) defined as a composite of all-cause death, revascularization, critically ill cardiovascular status, or stroke.

Interventions

DEVICEStent, red blood cell transfusion

BMS (Bare Metal Stent) and DES (drug-eluting stent) transplants with periprocedural red blood cell transfusion

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with percutaneous coronary intervention from 2006 to 2015 * Patients with the implantation of BMS or DES * Patients with the receipt of periprocedural red blood cell transfusion

Exclusion criteria

* Patients without any of stent implantation

Design outcomes

Primary

Measure	Time frame	Description
Incidence density of MACE (Major adverse clinical events)	3 years	The first major adverse clinical event(MACE) defined as a composite of all-cause death, revascularization, critically ill cardiovascular status, and stroke.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026